Experience

Davis Polk advised PPL Capital Funding, Inc. on its registered offering of $650 million aggregate principal amount of 3.100% senior notes due 2026, fully and unconditionally guaranteed by…

Davis Polk advised The Metropolis of Tokyo in connection with its $1 billion Rule 144A/Regulation S offering of 2.000% bonds due 2021. The offering was the Metropolis’s first-ever U.S…

Davis Polk advised the joint book-running managers on an SEC-registered offering of $400 million aggregate principal amount of 3.75% senior notes due 2046. Headquartered in Lake…

Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by The Travelers Companies, Inc. of $500 million aggregate principal…

Davis Polk advised the joint book-running managers on an SEC-registered offering by General Motors Financial Company, Inc. (“GM Financial”) of $400 million aggregate principal amount…

Davis Polk advised Texas Instruments Incorporated on its SEC-registered debt offering of $500 million aggregate principal amount of 1.850% notes due 2022.  Texas Instruments is a…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Knowles Corporation of $150 million aggregate principal amount of its 3.25%…

Davis Polk advised the Dealers in connection with the preparation of a new global medium-term note program (the “Program”) by the Emirate of Abu Dhabi (the “Issuer”). Davis Polk also…

Davis Polk advised the joint book-running managers in connection with a $115.1 million SEC-registered offering of 5,479,750 ordinary shares of Theravance Biopharma, Inc. The ordinary shares…